{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:06:28Z","timestamp":1784775988841,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug-induced epidermal necrolysis is a recently proposed entity designed to clearly differentiate medication-triggered Stevens\u2013Johnson syndrome and toxic epidermal necrolysis from infection-related and idiopathic disease, particularly in paediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize the clinical features of paediatric drug-induced epidermal necrolysis, a condition with relatively limited data in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analysed the electronic medical records of paediatric patients diagnosed with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in T\u00fcrkiye between 2018 and 2024. Patient cases were identified using ICD-10 codes from a national database, and only those with a confirmed drug-related aetiology were included. Clinical characteristics, suspected causative drugs, disease severity, in-hospital complications and treatment approaches were evaluated. Statistical analyses were performed to assess differences in clinical outcomes based on drug type and disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 33 paediatric patients were included. Antibiotics (45%, 15\/33) and antiepileptic drugs (36%, 12\/33) were the most commonly implicated medications. In-hospital complications occurred in 67% of patients (22\/33), with septicaemia being the most frequent. The patients with toxic epidermal necrolysis had significantly longer hospital stays. Statistical analyses revealed differences in clinical presentation and disease course based mainly on the causative drug, with patients with antiepileptic-induced cases exhibiting a later onset and fewer in-hospital complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights the distinct clinical characteristics of paediatric drug-induced epidermal necrolysis, emphasizing the impact of causative drugs on disease course and outcomes, which may aid in improving diagnosis and treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf274","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T07:57:35Z","timestamp":1750406255000},"page":"2179-2184","source":"Crossref","is-referenced-by-count":2,"title":["Paediatric drug-induced epidermal necrolysis: insights from real-world evidence in T\u00fcrkiye"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1154-0219","authenticated-orcid":false,"given":"Esra","family":"Kiratli Nalbant","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venerology, Ankara Yildirim Beyazit University, Faculty of Medicine , Ankara ,","place":["T\u00fcrkiye"]},{"name":"Dermatology and Venerology Clinic, Ankara Bilkent City Hospital , Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0675-3092","authenticated-orcid":false,"given":"Burcu","family":"Ozkan Kirgin","sequence":"additional","affiliation":[{"name":"Pediatric Allergy and Immunology Clinic, Ankara Etlik City Hospital , Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Sirin","sequence":"additional","affiliation":[{"name":"Pediatric Allergy and Immunology Clinic, Ankara Etlik City Hospital , Ankara ,","place":["T\u00fcrkiye"]},{"name":"Department of Pediatric Allergy and Immunology, Ankara Yildirim Beyazit University, Faculty of Medicine , Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-2821","authenticated-orcid":false,"given":"Naim","family":"Ata","sequence":"additional","affiliation":[{"name":"Department of Strategy Development, Republic of T\u00fcrkiye, Ministry of Health , Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suayip","family":"Birinci","sequence":"additional","affiliation":[{"name":"Ministry of Health , Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-648X","authenticated-orcid":false,"given":"Koray","family":"Harmanci","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy and Immunology, Eskisehir Osmangazi University, Faculty of Medicine , Eskisehir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-5053","authenticated-orcid":false,"given":"Zulfikar","family":"Akelma","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy and Immunology, Ankara Yildirim Beyazit University, Faculty of Medicine , Ankara ,","place":["T\u00fcrkiye"]},{"name":"Pediatric Allergy and Immunology Clinic, Ankara Bilkent City Hospital , Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"2025102707122824500_llaf274-B1","doi-asserted-by":"crossref","first-page":"e000039","DOI":"10.1136\/bmjpo-2017-000039","article-title":"Retrospective review of paediatric case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis with lamotrigine from an international pharmacovigilance database","volume":"1","author":"Egunsola","year":"2017","journal-title":"BMJ Paediatr Open"},{"key":"2025102707122824500_llaf274-B2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s13555-024-01180-6","article-title":"Evaluation of the factors influencing mortality in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter study of 166 patients","volume":"14","author":"Erduran","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025102707122824500_llaf274-B3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaad.2016.12.024","article-title":"Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States","volume":"76","author":"Hsu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025102707122824500_llaf274-B4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1159\/000531366","article-title":"A comprehensive assessment of long-term complications in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"184","author":"Cekic","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"2025102707122824500_llaf274-B5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/bjd.20063","article-title":"Blistering severe cutaneous adverse reactions in children: proposal for paediatric-focused clinical criteria","volume":"185","author":"Ramien","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025102707122824500_llaf274-B6","doi-asserted-by":"crossref","first-page":"982","DOI":"10.12688\/f1000research.20419.1","article-title":"Pediatric SJS-TEN: where are we now?","volume":"9","author":"Ramien","year":"2020","journal-title":"F1000Research"},{"key":"2025102707122824500_llaf274-B7","doi-asserted-by":"crossref","first-page":"1330517","DOI":"10.3389\/falgy.2024.1330517","article-title":"Recent findings on drug hypersensitivity in children","volume":"5","author":"Felix","year":"2024","journal-title":"Front Allergy"},{"key":"2025102707122824500_llaf274-B8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/pde.13383","article-title":"Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"35","author":"Antoon","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"2025102707122824500_llaf274-B9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/1346-8138.16476","article-title":"Clinical features and outcomes in children with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"49","author":"Chi","year":"2022","journal-title":"J Dermatol"},{"key":"2025102707122824500_llaf274-B10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaip.2017.02.013","article-title":"Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study","volume":"5","author":"Misirlioglu","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025102707122824500_llaf274-B11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/PEC.0000000000000840","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review","volume":"32","author":"Alerhand","year":"2016","journal-title":"Pediatr Emerg Care"},{"key":"2025102707122824500_llaf274-B12","first-page":"52","article-title":"Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"90","author":"Lucia","year":"2019","journal-title":"Acta Biomed"},{"key":"2025102707122824500_llaf274-B13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/jdv.20054","article-title":"Drugs associated with epidermal necrolysis in children: a World Health Organization pharmacovigilance database analysis","volume":"38","author":"Bataille","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707122824500_llaf274-B14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/BCR.0000000000000208","article-title":"A 15-year review of pediatric toxic epidermal necrolysis","volume":"36","author":"Quirke","year":"2015","journal-title":"J Burn Care Res"},{"key":"2025102707122824500_llaf274-B15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12519-016-0057-3","article-title":"Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20\u2005years study in a tertiary care hospital","volume":"13","author":"Techasatian","year":"2017","journal-title":"World J Pediatr"},{"key":"2025102707122824500_llaf274-B16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/bjd\/ljae321","article-title":"Recent progress in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment","volume":"192","author":"Hama","year":"2025","journal-title":"Br J Dermatol"},{"key":"2025102707122824500_llaf274-B17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/WOX.0b013e3181778282","article-title":"The p-i concept: pharmacological interaction of drugs with immune receptors","volume":"1","author":"Pichler","year":"2008","journal-title":"World Allergy Organ J"},{"key":"2025102707122824500_llaf274-B18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/tan.13530","article-title":"HLA-associated antiepileptic drug-induced cutaneous adverse reactions","volume":"93","author":"Mullan","year":"2019","journal-title":"HLA"},{"key":"2025102707122824500_llaf274-B19","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome","volume":"128","author":"Ko","year":"2011","journal-title":"JAllergy Clin Immunol"},{"key":"2025102707122824500_llaf274-B20","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2217\/pgs-2017-0090","article-title":"HLA-associated drug hypersensitivity and the prediction of adverse drug reactions","volume":"18","author":"Negrini","year":"2017","journal-title":"Pharmacogenomics"},{"key":"2025102707122824500_llaf274-B21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/pde.15693","article-title":"Characterizing drug-induced epidermal necrolysis in a pediatric cohort","volume":"41","author":"Brown","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"2025102707122824500_llaf274-B22","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.5415\/apallergy.2022.12.e17","article-title":"Clinical characteristics of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a single-center study","volume":"12","author":"Yoo","year":"2022","journal-title":"Asia Pac Allergy"},{"key":"2025102707122824500_llaf274-B23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/jbcr\/irae140","article-title":"Utility of the Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) in pediatric Stevens-Johnson syndrome patients","volume":"46","author":"Gust","year":"2025","journal-title":"J Burn Care Res"},{"key":"2025102707122824500_llaf274-B24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf274\/63537491\/llaf274.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2179\/63537491\/llaf274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2179\/63537491\/llaf274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:12:34Z","timestamp":1761563554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/11\/2179\/8170026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,20]]},"published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf274","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,20]]}}}